Psaty, Bruce M <br/><br/>
Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.  [electronic resource] 

 -  JAMA  Mar 2008 
 - 1474-6 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1538-3598 
<br/><br/><label>Standard No.: </label>10.1001/jama.299.12.1474  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Azetidines--therapeutic use<br/>Biomarkers<br/>Clinical Trials as Topic<br/>Drug Approval<br/>Ezetimibe<br/>Humans<br/>Hypolipidemic Agents--therapeutic use<br/>Quinolines--therapeutic use<br/>Risk<br/>United States<br/>United States Food and Drug Administration